Revolution in early diagnosis

Detect neurodegenerative diseases such as Alzheimer’s and Parkinson’s at a very early stage. Accurate, early diagnosis enables prevention and successful treatment. The innovative protein test from betaSENSE aims to make this possible. Simple, clear, successful. So that self-determination in old age becomes a matter of course.

Timely diagnosis enables early treatment.

When neurodegenerative diseases develop, the structure of certain biomarker proteins in the brain changes at a very early stage. betaSENSE’s iRS platform technology can precisely detect these initial, very small changes, known as misfolding of biomarker proteins, even in body fluids, especially blood. This simplifies access to clinical diagnosis and paves the way for timely action.

Simple test to provide certainty

Small amounts of bodily fluids are sufficient to detect clinical disease at a very early stage using the betaSENSE method.

Science as the key to progress

With the betaSENSE method, we are putting research into practice. The development of our platform technology is groundbreaking for cutting-edge research in the field of protein diagnostics.

Guide to prevention and treatment

This is because a very early diagnosis, before the brain has suffered irreversible damage, means that the course of the disease can be positively influenced through lifestyle adjustments and medication.

Be prepared for Alzheimer's.

Early certainty for a self-determined life.

Learn more

Parkinson´s.

Recognition enables effective treatment.

Learn more

That is
betaSENSE.

We want to revolutionise protein diagnostics. Our goal is the early detection of neurodegenerative diseases. Our innovative platform technology provides the basis for this.

Our latest publications.

EMBO Molecuar Medicine, 2025

Alpha-synuclein misfolding as fluid biomarker for Parkinson’s disease measured with the iRS platform

Go to article

Alzheimer’s & Dementia, 2022

Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years

Go to article

Annals of Clinical & Translational Neurology, 2021

TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis

Go to article

betaSENSE in the press

New Biomarker for Parkinsons Disease

A misfolded protein enables a secure diagnosis in early disease stages.

Go to article

Innovation Price 2023 NRW

Prof. Dr. Klaus Gerwert

Go to article

Spin-off betaSENSE moves into the BioMedicineCenter

Mayor Thomas Eiskirch ceremoniously handed over the keys to Managing Director Klaus Gerwert.

Go to article

Working
at betaSENSE.

Be part of the diagnostics revolution. Our team consists of around 30 employees with expertise in various scientific disciplines. We are united by a pioneering spirit and a desire to combat neurodegenerative diseases at an early stage.

Revolution in early diagnosis

Timely diagnosis enables early treatment.

Simple test to provide certainty

Science as the key to progress

Guide to prevention and treatment

That isbetaSENSE.

We want to revolutionise protein diagnostics. Our goal is the early detection of neurodegenerative diseases. Our innovative platform technology provides the basis for this.